Salarius Pharmaceuticals Inc

For the period ended Jun 30, 2024. Filed Aug 9, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 9, 2024

DCOY$1.11+0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

	Six Months EndedJune 30
	2024	2023
Operating activities
Net loss	$(3,139,723)	$(9,218,081)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,213	3,338
Equity-based compensation expense	162,676	326,804
Changes in operating assets and liabilities:
Grants receivable	—	1,480,490
Prepaid expenses and other assets	403,401	546,681
Accounts payable	16,613	(671,506)
Accrued expenses and other current liabilities	128,673	(53,608)
Net cash used in operating activities	(2,426,147)	(7,585,882)
Financing activities
Proceeds from issuance of equity securities, net	88,703	7,020,890
Payments on note payable	(289,643)	—
Net cash (used in) provided by financing activities	(200,940)	7,020,890
Net decrease in cash, cash equivalents and restricted cash	(2,627,087)	(564,992)
Cash, cash equivalents and restricted cash at beginning of period	5,899,910	12,106,435
Cash, cash equivalents and restricted cash at end of period	$3,272,823	$11,541,443
Supplemental disclosure of cash flow information:
Non-cash investing and financing activities:
Cash paid for interest	$4,816	$—
Accrued issuance costs for issuance of equity securities	$23,585	$100,419

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.